## About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

## Details of Drug Reviewed

<table>
<thead>
<tr>
<th>Drug</th>
<th>etanercept</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand Name</td>
<td>Erelzi™</td>
</tr>
<tr>
<td>Dosage Forms</td>
<td>50 mg/mL solution for injection prefilled auto-injector, 50 mg/mL solution for injection prefilled syringe, 25 mg/0.5 mL solution for injection prefilled syringe</td>
</tr>
<tr>
<td>Manufacturer</td>
<td>Sandoz Canada Inc.</td>
</tr>
</tbody>
</table>

### Submission Type
- **New Indication**

### Use Reviewed
- Psoriatic Arthritis (PsA)

### Common Drug Review (CDR)
- No, CDR did not review

### Provincial Review
- In October 2017, the Canadian Agency for Drugs and Technologies in Health (CADTH) provided confirmation to Sandoz that a CDR submission for Erelzi for the new indication of psoriatic arthritis is not required; as such, a full Drug Benefit Council (DBC) review is not required and the Ministry’s drug coverage decision will be based on an internal review only.

### Drug Coverage Decision
- **Limited Coverage Benefit.** Access the Erelzi criteria from [www.gov.bc.ca/pharmacarespecialauthority](http://www.gov.bc.ca/pharmacarespecialauthority)

### Date
- April 9, 2019

### Reasons
- The drug was similar to the reference drug, etanercept (Enbrel®), with respect to efficacy, safety, pharmacokinetics and immunogenicity.
- Based on a clinical trial for Erelzi, the results suggested that switching from Enbrel to Erelzi and vice-versa can be performed safely and without any loss of efficacy.
- Based on economic considerations and the product price, the drug was cost effective and offered value for money.

### Other Information
- None
The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the Drug Benefit Council (DBC) gives advice to the Ministry. The DBC looks at:
- whether the drug is safe and effective
- advice from a national group called the Common Drug Review (CDR)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:
- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit the The Drug Review Process in B.C. - Overview and Ministry of Health - PharmaCare for more information.

This document is intended for information only. It does not take the place of advice from a physician or other qualified health care provider.